Follow
"In the case before the US Supreme Court, Amgen is appealing against a federal court ruling that struck down one of its key patents on Repatha. The patent claims not only a handful of specific antibodies, as defined by their amino-acid sequence, but also any other antibodies, regardless of their structure, that bind to the same region of the PCSK9 protein."
